IPALT

iPALT, or ALiPT, also known as N-isopropyl-N-allyltryptamine or by its developmental code name ASR-3003, is a serotonin receptor modulator of the tryptamine family.

Uses your system voice; voice and rate in settings.

Snapshot

≈ 13 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

Pharmaceutical compound

iPALT, or ALiPT, also known as N-isopropyl-N-allyltryptamine or by its developmental code name ASR-3003, is a serotonin receptor modulator of the tryptamine family.[1] It is an asymmetrical analogue of diisopropyltryptamine (DiPT) and diallyltryptamine (DALT).[1] The drug is a non-selective serotonin receptor agonist, including of the serotonin 5-HT1B, 5-HT2A, 5-HT2B, and 5-HT6 receptors, but not of the serotonin 5-HT1A receptor.[1] It is also a serotonin reuptake inhibitor, but does not inhibit dopamine or norepinephrine reuptake.[1] The drug shows rather low potency for many of these actions, with for example 47-fold lower potency as a serotonin 5-HT2A receptor agonist than the known psychedelic drug 5-MeO-iPALT (ASR-3001).[1] The chemical synthesis of iPALT has been described.[1] Derivatives of iPALT include 5-MeO-iPALT (ASR-3001), 4-HO-iPALT, and 2-Me-iPALT (ASR-3002).[1] 5-MeO-iPALT is known to be a psychedelic drug in humans and is under development for potential medical use.[2][3][4][5] iPALT was patented by the Alexander Shulgin Research Institute (ASRI) in 2024.[1]

See also

edit edit source

References

edit edit source
  1. ^ a b c d e f g h US 20240277665A1, Daley PF, Cozzi NV, Callaway WB, "Asymmetric allyl tryptamines", issued 4 March 2024, assigned to Alexander Shulgin Research Institute Inc.  Wikipedia revision 1360364413, retrieved 2026-11-19
  2. ^ "Delving into the Latest Updates on Tryptamine(ASRI) with Synapse". Synapse. 16 April 2025. Retrieved 19 April 2025. Wikipedia revision 1360364413, retrieved 2026-11-19
  3. ^ Goldstein L (10 July 2023). "Pioneering Psychedelics Scientist Alexander "Sasha" Shulgin's Legacy Lives On Via New Compounds And Research". Benzinga. Retrieved 19 April 2025. Wikipedia revision 1360364413, retrieved 2026-11-19
  4. ^ Busby M (2 November 2023). "The Heirs to a Vault of Novel Psychedelics Take a Trip Into the Unknown". DoubleBlind Mag. Retrieved 19 April 2025. Wikipedia revision 1360364413, retrieved 2026-11-19
  5. ^ Busby M (30 March 2025). "What Happens When You Inherit 500 Psychedelic Compounds?". DoubleBlind Mag. Retrieved 19 April 2025. Wikipedia revision 1360364413, retrieved 2026-11-19
edit edit source Serotonin receptor modulators5-HT1 5-HT1B 5-HT1D 5-HT1E 5-HT1F 5-HT2 5-HT2B 5-HT2C 5-HT3–7 5-HT4 5-HT5A 5-HT6 5-HT7 Monoamine reuptake inhibitorsDATTooltip Dopamine transporter
(DRIsTooltip Dopamine reuptake inhibitors) NETTooltip Norepinephrine transporter
(NRIsTooltip Norepinephrine reuptake inhibitors) SERTTooltip Serotonin transporter
(SRIsTooltip Serotonin reuptake inhibitors) VMATsTooltip Vesicular monoamine transporters Others See also: Receptor/signaling modulators • Monoamine releasing agents • Adrenergics • Dopaminergics • Serotonergics • Monoamine metabolism modulators • Monoamine neurotoxins TryptaminesTryptamines 4-Hydroxytryptamines
and esters/ethers 5-Hydroxy- and
5-methoxytryptamines N-Acetyltryptamines α-Alkyltryptamines α-Ketotryptamines Cyclized tryptamines Isotryptamines Related compounds

Text derived from https://en.wikipedia.org/w/index.php?oldid=1360364413 under CC BY-SA 4.0; modifications have been made.